Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

20141,068 citationsJournal Articlebronze Open Access

Authors

Fotios Loupakis · Azienda Ospedaliera Universitaria Pisana

Chiara Cremolini · Azienda Ospedaliera Universitaria Pisana

Gianluca Masi · Azienda Ospedaliera Universitaria Pisana

Sara Lonardi · University of Padua

Vittorina Zagonel · University of Padua

Lisa Salvatore · Azienda Ospedaliera Universitaria Pisana

Enrico Cortesi

Abstract

FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus bevacizumab, improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events. (Funded by the Gruppo Oncologico Nord Ovest and others; ClinicalTrials.gov number, NCT00719797.).

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 17, pp. 1609-1618

DOI: 10.1056/nejmoa1403108

Field-Weighted Citation Impact: 40.92